Core Viewpoint - Telix Pharmaceuticals Limited is facing a class action lawsuit due to alleged securities fraud, with a deadline for investors to file a lead plaintiff motion by January 9, 2026 [1][5]. Summary by Sections Company Developments - On July 22, 2025, Telix disclosed receiving a subpoena from the U.S. Securities and Exchange Commission (SEC) regarding its disclosures related to prostate cancer therapeutic candidates, leading to a stock price drop of $1.70, or 10.4%, closing at $14.58 on July 23, 2025 [2]. - On August 28, 2025, Telix announced it received a Complete Response Letter (CRL) from the FDA concerning its Biologics License Application (BLA) for TLX250-CDx, which identified deficiencies in the Chemistry, Manufacturing, and Controls (CMC) package. This announcement caused the stock price to fall by $1.95, or 16.1%, closing at $10.15 on the same day [3]. Allegations in the Lawsuit - The class action complaint alleges that during the Class Period, Telix's management made materially false and misleading statements and failed to disclose adverse facts about the company's business and prospects. Specific allegations include: 1. Overstating the progress made on prostate cancer therapeutic candidates. 2. Overstating the quality of Telix's supply chain and partners. 3. Misleading investors regarding the company's business and operational prospects [4].
Deadline Alert: Telix Pharmaceuticals Limited (TLX) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit